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Abstract: In dementia, neuropathological changes alter the perception and expression of 
pain. For clinicians and family members, this knowledge gap leads to difficulties in recog-
nizing and assessing chronic pain, which may consequently result in persons with dementia 
receiving lower levels of pain medication compared to those without cognitive impairment. 
Although this situation seems to have improved in recent years, considerable geographical 
variation persists. Over the last decade, opioid use has received global attention as a result of 
overuse and the risk of addiction, while the literature on older persons with dementia actually 
suggests undertreatment. This review stresses the importance of reliable assessment and the 
regular evaluation and monitoring of symptoms in persons with dementia. Based on current 
evidence, we concluded that chronic pain is still undertreated in dementia. 
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Introduction
In 1901, Auguste Deter, a 51-year-old woman committed to the Frankfurt 
Asylum, was showing short-term memory problems and unusual behavioral 
symptoms. A medical doctor at the asylum, Alois Alzheimer, was intrigued by 
her case and closely followed the patient, eventually studying post-mortem brain 
autopsy material.1 The clinical picture, combined with amyloid plaques and 
neurofibrillary tangles in the brain, was the first description of what we now 
refer to as ‘Alzheimer’s disease’, one of the many forms of dementia.2 
Unfortunately, it is not known whether Auguste also had pain, and if so, 
whether this was noticed by Dr Alzheimer or other caregivers. If something 
had been noticed, would it have been recognized as pain? And if recognized, 
would it have been treated?
In this review, we discuss the problems surrounding the perception, expression, 
recognition and treatment of pain in persons with dementia, with the ultimate goal 
of answering the question “Are chronic pain patients with dementia currently 
undermedicated?”.
Methodology
For the purposes of this narrative review, we carried out a literature search in 
PubMed using the search terms pain, dementia, management, medication and 
undertreatment. As an abundance of review papers have appeared over the last 15 
years, we decided to specifically focus on studies published between 2015 and 
August 2020.
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However, we should provide some background on why 
the undertreatment of pain in dementia is an important 
topic. We will first describe the epidemiology and neuro-
pathology of dementia, followed by the changes in pain 
perception and expression in dementia that have conse-
quences for assessment.
Epidemiology of Dementia
Dementia as a syndrome involves a range of functional 
impairments that affect memory and executive functions 
(amongst other cognitive functions), motor and sensory 
aspects, and communicative, behavioral and psychological 
functions.3 The disease trajectory is very heterogeneous 
and thus unpredictable, but diagnosis to death usually 
takes up to 10 years, depending on personal and disease- 
related factors.4 Many diseases characterized by specific 
neuropathological changes can lead to the syndrome of 
dementia, of which Alzheimer’s disease is the most 
common.5 Although Alzheimer’s was described over 100 
years ago and the formation of tangles and plaques was 
already recognized in the Auguste Deter case, disease 
onset and the complete etiological pathway is still not 
fully understood. Therefore, a cure is also currently 
beyond reach.
Vascular dementia, Lewy-body dementia and fronto-
temporal dementia are other more or less prevalent dis-
eases that cause dementia, although there is substantial 
heterogeneity in causes worldwide.3 Vascular dementia is 
typified by white matter damage as a consequence of 
vascular pathology, such as long-term hypertension. 
Alzheimer’s dementia and vascular dementia are so com-
mon that the mixed presence of these two forms of demen-
tia may, in fact, be the most prevalent clinical picture in 
older individuals.3 Other neurodegenerative diseases, such 
as Parkinson’s disease and Huntington’s disease, may in 
the later stages also lead to a form of dementia.6,7
Changes in Pain Perception in 
Dementia
The neuropathological changes in various types of demen-
tia disrupt elaborate neural pain networks,8 such as the 
lateral and medial pain networks involved in pain percep-
tion. The lateral network is the oldest evolutionary pain 
system and indeed the most ‘basic’, as it mediates the 
sensory-discriminative aspects of pain, such as localiza-
tion, intensity and quality of pain. It is located in the 
primary somatosensory cortex and the (lateral) thalamus, 
amongst other sites. Cognitive, evaluative and motiva-
tional-affective aspects of pain are thought to be mediated 
via the medial network, which is comprised of the pre-
frontal cortex and several subcortical structures such as the 
amygdala, hippocampus and thalamus.9 A third pain net-
work comprised of various systems including the striatum 
is believed to be the rostral, or limbic pain system, which 
mediates behavioral reactions to pain.10
In Alzheimer's dementia, the medial pain network 
shows greater neuropathology and more damage than the 
lateral network. At one time, researchers assumed that 
Alzheimer's patients might have an unchanged pain thresh-
old but with a higher pain tolerance due to the damaged 
cognitive-evaluative functions. Although early experimen-
tal studies seemed to confirm this theory, later studies of 
EEG responses to pain, pain reflexes, studies of facial 
responses to noxious stimuli and fMRI studies during 
pain stimuli all showed that if there is a change, it is 
probably towards a lower pain tolerance and the level of 
suffering is likely to be higher.11,12
As a key player in the rostral or limbic pain system, 
and specifically associated with pain behavior, the striatum 
is affected by Alzheimer’s disease. However, studies have 
produced conflicting results, showing either a lower or 
higher activation of the striatum in response to pain, 
depending on the stage of dementia. It is generally 
believed that activation of the striatum in response to 
pain is stronger in mild to moderate Alzheimer’s disease, 
but is normal or even absent in later stages. This is in line 
with clinical observations and some clinical studies which 
suggest that behavioral reactions to pain are blunted in the 
later stages of Alzheimer’s disease.11
Changes in Pain Expression in 
Dementia
During the course of dementia, the ability to recognize, 
evaluate and verbally express one’s own pain gradually 
decreases.11,12 Thus, whereas self-reported pain is viewed 
as the most valid channel of pain expression in cognitively 
healthy individuals, this channel loses its validity in 
dementia and other non-verbal channels of pain expression 
become more important. The best-studied alternative has 
been the facial expression of pain,13,14 and several studies 
have used experimental designs that involved pain induc-
tion based on mechanical pressure, electrical stimulation, 
flu injection, venipuncture or the exacerbation of chronic 
musculoskeletal pain during physical exercise. During the 
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experimental induction of pain, facial expressions were 
videotaped and later analyzed by specially trained raters 
using the Facial Action Coding System (FACS).15 FACS is 
an anatomically based method designed to objectively 
describe detailed facial muscle movements and is widely 
seen as the gold standard when assessing facial responses 
to pain.16 Four facial movements have been repeatedly 
observed in the context of pain, consisting of 
a tightening of the muscles surrounding the eyes, furrowed 
brows, raising the upper lip/nose wrinkling and an opened 
mouth.16 It is important to realize that these facial move-
ments are not typically displayed together when somebody 
is in pain, as individuals usually show different mixtures 
of each facial movement.17,18 The most frequent response 
to pain is a tightening of the muscles around the eyes, 
paired with one or two other pain-indicative facial 
movements.
Impact of Dementia on Facial Responses
Findings on the impact of dementia on facial responses to 
pain are surprisingly homogeneous, despite the use of 
different pain induction methods and the study of mixed 
samples of patients suffering from dementia. It has been 
consistently found that as pain intensity increases, facial 
responses intensify in patients with dementia.13–18 This 
clearly indicates that facial expressions in patients with 
dementia reliably convey pain intensity. Furthermore, the 
facial responses to pain in patients with dementia are the 
same as those in individuals without dementia.13,15,16 In 
terms of the strength and extent of facial responses to pain 
in patients with dementia, it was found that patients actu-
ally show increased facial displays of pain compared to the 
cognitively unimpaired.13,14 The increased facial expres-
sion of pain might suggest an intensified processing of 
noxious stimuli and/or a loss of inhibitory mechanisms 
that govern the degree to which we express pain via facial 
expressions. In summary, while individuals with dementia 
and cognitively healthy individuals express pain using the 
same types of facial muscle movements, individuals with 
dementia show more vigorous and intense responses.
New Developments in Recognition/ 
Assessment in Dementia
An essential requirement for acceptable pain management is 
a well-performed pain assessment that covers the different 
aspects of pain (eg intensity, location, affect, cognition, beha-
vior, social accompaniments). However, communication 
difficulties and cognitive impairment in patients with dementia 
mean that it is not possible to focus on all of these aspects. 
Thus, limited and one-sided pain assessment (focusing only on 
the presence and intensity of pain) cannot be avoided in 
individuals with dementia. Below we discuss several of the 
best pain assessment practices for persons with dementia.
Self-Report
Despite early declines in cognitive and language capaci-
ties, self-report should still be used, or at least attempted, 
in patients in the earlier phases of dementia (mild to 
moderate).19 It is advisable to use less cognitively challen-
ging scales such as simple numerical scales (eg numerical 
rating scales (NRS) ranging from “0” (no pain) to “10” 
(extremely strong pain)) or verbal category scales (eg 
a 5-point Likert scale: “no pain”, “mild pain”, “moderate 
pain”, “strong pain”, “very strong pain”). As dementia 
progresses, simple questions that only require categorical 
answers such as ‘yes/no’ should be used.
Observational Scales
As cognitive and communication skills weaken due to the 
progression of dementia, self-report questions should be 
accompanied by assessment tools based on clinical 
observation.20 In the later stages of dementia, observa-
tional pain assessment takes a leading role in pain assess-
ment. These scales mainly use facial expressions and vocal 
responses to pain, in addition to body posture and 
movement.20,21 One of the difficulties with these observa-
tional instruments, of which there are more than ten, lies in 
psychometric properties that are often poor or untested.20 
These include inter- and intra-rater reliability, validity and 
sensitivity to change. The best available observational pain 
instruments, although not perfect, are PAINAD,22,23 
PACSLAC,24 and DOLOPLUS-2.25,26 Another issue 
related to poor pain management in persons with dementia 
is a poor implementation in practice. That is unfortunate 
because the comprehensive and systematic implementation 
of these tools improves clinical practice. The focus should, 
therefore, not only be on psychometric testing but should 
also certainly include informing and educating the main 
end-user group, the long-term care and geriatric nurses. 
This group should be tasked with applying these tools but 
can also help further improve the usability of these tools.11
The last 5 years have seen two initiatives designed to 
tackle the problem of imperfectly developed observational 
tools. Both approaches used a meta-tool concept, which 
involves selecting the best items from existing observer 
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rating scales. A USA-based group developed the ‘Pain 
Intensity Measure for Persons with Dementia’ (available 
in English),27 while a European group developed the ‘Pain 
Assessment in Impaired Cognition’ (PAIC-15; available in 
English and 8 other languages, including Chinese and 
Japanese).28,29 Both instruments are very promising, and 
a number of studies of their properties and clinical useful-
ness are currently underway.
Automatic Pain Recognition
When communication becomes difficult and behavioural 
observation complicated, one might consider more techni-
cal solutions to recognize and assess signals of pain. 
However, despite a considerable promise in non- 
communicative patients, the automation of pain recogni-
tion faces many challenges.30 The most promising of these 
automated pain tools involves the monitoring of facial 
expressions, sometimes together with other biological 
cues such as blood pressure, heart and cerebral function 
(ECG and EEG), and occasionally, actigraphy.31 Currently, 
machine learning algorithms are often developed under 
laboratory conditions in terms of surroundings, are 
designed to assess bedridden patients and often lack real- 
life emotional expressions. In addition, this form of com-
puter-driven pain diagnostic has mainly been developed in 
a young population, without taking account of the specifics 
of older populations. This may lead to the so-called ‘wrin-
kle’ bias, which is a lack of validation for older faces.30 
Together, these issues mean that the use of these tools in 
clinical geriatric practice remains in the distant future and 
progress in this promising field will only be possible based 
on collaboration between the relevant clinicians (nurses, 
physicians, psychologists) and computer, engineering and 
artificial intelligence scientists.
New Developments in Pain 
Management: Is Undertreatment an 
Issue?
In an earlier review in 2013, we described several studies, 
encompassing a number of care settings, that reported 
undertreatment of patients with dementia compared to 
persons without cognitive impairment.11 Four studies pro-
vided particularly clear evidence of a lower use of analge-
sics in persons with dementia compared to those without 
dementia.32–35 However, one study showed almost no 
difference,31 and two reported a higher use of pain medi-
cation in persons with dementia.32,33 There were almost no 
data on the use of non-pharmacological management, but 
the conclusion was that, in general, undertreatment of 
persons with dementia is very common. Undertreatment 
is thought to be driven by complications surrounding the 
recognition and assessment of pain, together with reserva-
tions concerning polypharmacy and the side effects of 
medication. We and others concluded that poor pain man-
agement of persons with dementia places a substantial 
burden on their quality of life.36 However, in the last few 
years, the rapidly growing use of opioids has received 
considerable attention – prompting us to revisit opioid 
treatment of persons with dementia.
Treatment with Opioids
Opioid analgesics are commonly used for acute and 
chronic non-cancer pain in people with dementia, although 
their efficacy and safety, particularly during long-term use, 
is supported by little evidence or documentation.20,37 
Because clinical evidence is lacking, no dementia- 
specific treatment guidelines exist for moderate to severe 
acute or chronic pain.20 In 2019, the International 
Association for the Study of Pain published a fact sheet 
on ‘Pain Management in Dementia’ as part of the ‘Global 
Year Against Pain in the Most Vulnerable’, stating that 
while strong opioids may be used cautiously, weak opioids 
(eg codeine, tramadol) should be avoided in those with 
dementia due to high interindividual variation in treatment 
effect due to metabolic activation, little evidence for effec-
tiveness, and a high risk of adverse effects and drug inter-
act ions (ht tps: / /www.iasp-pain.org/GlobalYear/  
MostVulnerable). In practice, prescription rates vary 
widely, both between and within countries and regions.
Discrepancies Between Nations
Several studies published in the last 5 years illustrate the 
major inconsistencies in prescribing practices and pain 
management guidelines between nations. In Poland, less 
than 3% of a sample of nursing home patients with mild 
cognitive impairment or dementia (MMSE ≤ 23) were 
treated with an opioid, with the majority receiving only 
the weak opioid tramadol.37 The same study found that 
90% of patients with severe cognitive impairment received 
no analgesic treatment, compared to 76% of those with no 
cognitive impairment (p<0.01).38 In 2012, an Italian study 
also showed low opioid prescription in a sample of hospi-
talized geriatric patients, 6.6% of whom received an opioid 
at discharge. The corresponding rate in 116 patients diag-
nosed with dementia was only 2.6% (χ2 test, p=0.126).39 
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In contrast, a recent study from Austria reported a high use 
of opioids among 425 nursing home patients from 12 
nursing homes, with 50.2% receiving permanently sched-
uled opioid prescriptions, with no significant differences 
between people with no/slight and moderate-to-severe 
cognitive impairment.38
USA
A recent study from the USA, by Mehta et al (2020), 
investigated a cohort of 734,739 long-term nursing home 
residents (from 2011 to 2017) and found that advanced 
dementia was associated with a less opioid prescription. 
As analyses were controlled for the presence of pain, this 
finding potentially reflects suboptimal pain treatment.40 
Between 2011 and 2017, there was a 7.5% relative reduc-
tion in any opioid use among people with no dementia 
(from 48.2% to 44.6%), a 14.1% relative reduction among 
those with mild dementia (from 38.9% to 33.4%), a 13.1% 
relative reduction among people with moderate dementia 
(from 28.3% to 24.6%), and a 10.8% relative reduction 
among people with severe dementia (from 24.1% to 
21.5%).40 These results are supported by Hunnicutt et al 
(2018) who investigated opioid use in a sample of 315,949 
Medicare beneficiaries with long-term nursing home stays 
in 2012 and found that among those with persistent pain, 
38.7% of people with no/mild cognitive impairment used 
opioids long-term; in moderate and severe dementia the 
corresponding rates were significantly lower at 34.1% and 
31.1%, respectively.41 Shen et al (2018) investigated 
a sample of 19,347 elderly community-dwelling 
Medicare beneficiaries (2006 to 2013) and found that 
people with Alzheimer’s disease and related dementias 
(ADRD) were significantly less likely to receive opioids 
than those without ADRD (32.8% vs 33.4%), when ana-
lyses were controlled for general health status (OR 0.82, 
95% CI 0.71–0.94).42
The Opioid Epidemic in Dementia
While the overall use of opioids in community-dwelling 
elderly people increased from 2006 to 2013,42 declining 
trends for opioid prescribing were reported in nursing 
home patients with and without dementia from 2011 to 
2017,40 potentially reflecting a change in prescribing prac-
tice as a result of increased attention for the prevention of 
opioid addiction and opioid overdose deaths associated 
with the opioid epidemic in the USA. Despite an apparent 
shift in prescribing practice, the likelihood of receiving 
opioid treatment remains significantly lower in people 
with dementia compared to people without dementia 
across care settings, particularly in people with severe 
cognitive impairment.40–42
Canada
In Canada, a recent report on opioid use in nursing home 
patients describes lower prescribing rates compared to the 
USA, with a contrasting trend towards increased use among 
people with and without dementia.43 In Ontario, Iaboni et al 
(2019) found that overall prescription of opioids to long- 
term care residents increased from 15.8% in 2009/10 to 
19.6% in 2016/17 (<0.001); in people without dementia 
a 21.8% increase, from 21.3% to 26.0%, was reported 
(<0.001), while people with dementia had a reported 
38.5% increase, from 11.8% to 16.3% (p<0.001), indicating 
that they are still significantly less likely to receive opioid 
treatment compared to people without dementia.43
Nordic Countries
In the Nordic countries, multiple studies over the last 5 
years have reported few differences in opioid prescribing 
rates between people with and without dementia. Studies 
in nursing homes in Norway and Denmark have reported 
that elderly people with dementia are less likely to receive 
opioids than people without dementia, but this difference 
appears to be mainly driven by less use of weak opioids in 
nursing home residents with dementia.44,45 The most 
recent estimate from Norway, based on data from a 2011 
cohort, reported opioid use in 23.8% of nursing home 
patients and found that having dementia was not asso-
ciated with a significant difference in the likelihood of 
receiving a strong opioid.44 In a study involving the entire 
population of Denmark in 2010, 37.8% of nursing home 
residents with dementia received any opioid compared to 
43.0% of those without dementia (p<0.05). However, there 
was no significant difference for strong opioids (27.8% vs 
28.1%, p>0.05).44 The same study found that people with 
dementia in the community-dwelling population were 
more likely to receive opioid analgesics compared to 
those without dementia (27.5% vs 16.9%, adjusted OR 
1.27, 95% CI 1.22–1.31).44 Updated Danish registry data 
(2017) showed that use of opioids was still significantly 
higher in elderly people with dementia compared to 
elderly without dementia, although this study did not 
adjust for living status.46
In Finland, Hamina et al (2017) investigated opioid use 
among all community-dwelling people diagnosed with 
Alzheimer’s disease (AD) compared to matched controls 
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from 2005 to 2011 (62,074 persons with and 62,074 per-
sons without AD).47 They found that although long-term 
opioid use was more common among persons without AD 
(8.7% vs 7.2%, P<0.001), among opioid users with AD 
a higher proportion were long-term users (34.2% vs 
32.3%, P<0.001).47 Moreover, long-term use of transder-
mal opioids was more than twice as prevalent among 
opioid users with AD (13.2% vs 5.5%, p<0.0001).47 
Roitto et al (2019) investigated 14-year trends (2003–-
2017) in opioid use among institutionalized older people 
in Helsinki.48 Over this period, opioid use increased sig-
nificantly amongst people with and without dementia, liv-
ing in both nursing homes and assisted living facilities. In 
nursing homes and assisted living facilities, fewer people 
with dementia used opioids compared to those without 
dementia, and opioid use in nursing homes increased 
more rapidly among residents with dementia compared to 
those without dementia (p<0.01).48
Regional Differences
Data from the 2010 population study in Denmark have 
also been used to estimate municipal and regional differ-
ences in opioid prescribing. Interestingly, differences 
between municipalities were most pronounced among 
home-dwelling elderly people with dementia, with 
a 4-fold difference observed (ranging from 9.4% to 
36.8%) compared to a 1.6-fold difference among home- 
dwelling elderly people without dementia (ranging from 
12.7% to 20.2%).49 Among nursing home patients an 
equal and approximately 2-fold difference was observed, 
ranging from 26.5% to 55.2% for people with dementia 
and from 31.8% to 60.4% for nursing home patients not 
diagnosed with dementia.49 As the largest variations were 
found between municipalities rather than between larger 
regions, the authors suggested that primary care practice, 
which is organized at the municipal level, is the likely 
explanation for inconsistencies. No comparable study has 
been conducted in any other country. Nevertheless, given 
the large variations in prescribing practice between coun-
tries as outlined in this review, it is clear that there is a lack 
of coherent clinical guidelines for the assessment and 
treatment of pain in people with dementia, and/or a lack 
of implementation of such guidelines in clinical practice. 
Both prescribing traditions and practices within national 
medical communities, and differences between individual 
clinicians, likely contribute to the large observed varia-
tions in opioid treatment.
Undertreatment or Overtreatment?
A further important issue is whether countries with high 
opioid prescription rates actually achieve optimal treat-
ment of pain. To exemplify, a study of 327 nursing home 
patients with dementia and behavioral disturbances in 
Norway found that of the patients' prescribed opioids 
(19.3% of the total), 79.4% were still in pain.48 Practice 
differences in the management of moderate-to-severe 
(chronic) pain are illustrated by studies that compared 
the post-operative treatment of pain (after fracture) in 
people with and without dementia. In Denmark, Jensen- 
Dahm et al (2016) investigated the postoperative treatment 
of pain during the first 72 hours after hip fracture among 
all elderly patients treated in the Copenhagen University 
Hospital region in 2009.50 The study found that although 
people with dementia were equally likely to receive para-
cetamol and opioids, they received slightly lower dosages 
and more often received the medication pro re nata or “as 
needed”. Analyses were controlled for living status, which 
did not impact the results. In Finland, Lintula et al (2020) 
investigated the prevalence of opioid use in community- 
dwelling persons (2342 with AD and 1615 without AD) 
with hip fracture during the first 6 months after discharge 
from the hospital.51 The study found that opioid use was 
significantly more common among people with AD com-
pared to those without AD (39.5% vs 31.2%, χ2 test, 
p<0.0001), and that people with AD were more likely to 
use strong opioids during the first 3 months after dis-
charge. Buprenorphine use was more frequent in people 
with AD during the entire follow-up period, while people 
with AD used weak opioids less frequently during the first 
month after discharge compared to those without AD. In 
the USA, Mehta et al (2020) investigated opioid use 
among long-term care residents during a year in which 
a fracture was diagnosed during an emergency department 
visit, and found that within 7 days of discharge, 53.3% of 
people without dementia used an opioid, while corre-
sponding figures for people with mild, moderate, and 
severe dementia were 47.5%, 43.6%, and 35.7%, 
respectively.40 In Australia, Inacio et al (2016) found that 
having dementia was a risk factor for new chronic opioid 
use following total hip arthroplasty (OR=2.19, 95% CI 
1.06 to 6.39).51
This review has highlighted trends and developments 
in opioid treatment for elderly people with dementia over 
the last 5 years. We found that there is still considerable 
geographic variation in the use of opioids, both between 
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and within countries, and wider variation among people 
with dementia compared to those without dementia. Rates 
of reported opioid use among nursing home patients with 
dementia ranged from less than 3% in Poland to 55% in 
Denmark.38,49 Furthermore, several studies reported 
a gradient of decreasing opioid use with more severe 
cognitive impairment.40,41 While the ideal level of opioid 
treatment in people with dementia has yet to be deter-
mined, current evidence shows that undertreatment of 
pain in people with dementia is still an important clinical 
issue, although the extent of the problem varies with pre-
scribing practice both between countries and clinical set-
tings. It is important to note that greater use of opioids is 
not equivalent to appropriate use – several studies have 
reported that people with dementia are more likely to 
continue strong opioid treatment long term, and that trans-
dermal buprenorphine is strongly associated with chronic 
opioid use.47,51,52 This may indicate insufficient re- 
evaluation of appropriate opioid treatment in people with 
dementia and might suggest that a vulnerable group is at 
risk of drug-related harm.53
Non-Pharmacological Treatments
Given the fact that older persons have more comorbidity 
and less organ capacity, they are more prone to both 
polypharmacy and the negative effects of 
polypharmacy.54 In addition, people with dementia are 
not only more susceptible to side-effects because of their 
age but also due to their brain disease which makes them 
more vulnerable to delirium.55 Therefore, when they are 
effective, non-pharmacological interventions should be 
the first choice. Regarding behavioral problems, many 
non-pharmacological interventions have been shown to 
be effective in people with dementia,56 although imple-
mentation in practice presents challenges.57 Non- 
pharmacological interventions for pain have been 
reported, but evidence concerning people with dementia 
is unfortunately scarce.20 A recent study in a care home 
setting showed efficacy for massage and exercise on both 
pain and as-needed medication.58 Interestingly, the effects 
were stronger in the half of the sample with dementia. 
Another study found evidence for the effectiveness of 
massage and human interaction, but not for 
aromatherapy.59 Also, a relatively small study found sig-
nificant effects on pain of the PARO robot seal in 
a population with dementia.60
Interestingly, interventions effective for behavioral pro-
blems in dementia are also commonly effective on pain, 
and vice versa.61 Nowadays, complex behavioral problems 
are believed to be best handled by stepwise, multi-aspect 
programs, with a large non-pharmacological component.62 
Some have also shown a beneficial effect on pain.63 Over 
the next decade, we hope to see a greater emphasis on 
high-quality studies evaluating the efficacy and feasibility 
of non-pharmacological interventions.
Conclusion
This update of recent literature supports continuing con-
cerns regarding the proper management of pain in persons 
with dementia. Clinicians seem to still have difficulties 
evaluating the expression and intensity of pain, and diffi-
culties monitoring the effects of analgesic medication, in 
persons with dementia. Literature suggests that both start-
ing and stopping opioid use is complicated, as reflected in 
the long-term use of opioid patches reported in several 
studies.64 Therefore, better use should be made of our 
current understanding of the mechanisms of pain expres-
sion, and available clinical observational assessment 
instruments could be better implemented. The use of 
more elaborate technical pain-sensing systems is promis-
ing but unfortunately still remains in the realms of science 
fiction. Non-pharmacological interventions should be more 
promoted as management or co-management options both 
in research and clinical practice.
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